NCT05563623 is a clinical trial in Angle-Closure Glaucoma, sponsored by Peking University People's Hospital.

Who is sponsoring NCT05563623?

NCT05563623 is sponsored by Peking University People's Hospital.

What condition does NCT05563623 study?

NCT05563623 studies Angle-Closure Glaucoma.

Is NCT05563623 still recruiting?

NCT05563623 is currently recruiting now. Last updated 3 October 2022.

Last reviewed 2022-10-03 · How we verify

NCT05563623

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Beijing Angle Closure Progression Study

Recruiting now Last updated 3 October 2022

What this trial tests

trial in Angle-Closure Glaucoma in 825 participants. Currently enrolling.

Timeline

4 August 2022

Primary endpoint
31 December 2025

31 December 2030

Quick facts

Lead sponsor	Peking University People's Hospital
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	825
Start date	4 August 2022
Primary completion	31 December 2025
Estimated completion	31 December 2030
Sites	1 location across China

Conditions studied

Angle-Closure Glaucoma — all drugs for Angle-Closure Glaucoma →

Sponsor

Peking University People's Hospital

Who can join

Adults 40 to 75, any sex, with Angle-Closure Glaucoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Beijing angle closure progression study (BAPS) aims to explore the 5-year incidence of PACS progressing to PAC or PACG and to determine the possible risk factors of disease progression, which may provide the evidence for choosing the accurate strategies in the management of PACS.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Prospective study on the role of preoperative mannitol in capsulorhexis and reducing intraoperative complications in primary angle-closure disease surgery.
Liang Z, Li H, Hou X, Yang K, et al · · 2025 · cited 1× · PMID 39817367 · DOI 10.1177/03000605241310106
The Beijing angle closure progression study: design and methodology.
Liang ZQ, Yang KY, Lv K, Ma Y, et al · · 2024 · PMID 39086940 · DOI 10.3389/fmed.2024.1385060

Verify or expand the search:

Other Peking University People's Hospital trials

Trials by the same sponsor.

NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05563623 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
Last refreshed: 3 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05563623.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing